Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry

    Access Status
    Fulltext not available
    Authors
    Chin, K.
    Wolfe, R.
    Reid, Christopher
    Tonkin, A.
    Hopper, I.
    Brennan, Angela
    Andrianopoulos, N.
    Duffy, S.
    Clark, D.
    Ajani, A.
    Liew, D.
    Date
    2018
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Chin, K. and Wolfe, R. and Reid, C. and Tonkin, A. and Hopper, I. and Brennan, A. and Andrianopoulos, N. et al. 2018. Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. Cardiovascular Drugs and Therapy: pp. 1-8.
    Source Title
    Cardiovascular Drugs and Therapy
    DOI
    10.1007/s10557-018-6769-y
    ISSN
    0920-3206
    School
    School of Public Health
    URI
    http://hdl.handle.net/20.500.11937/65436
    Collection
    • Curtin Research Publications
    Abstract

    © 2018 Springer Science+Business Media, LLC, part of Springer Nature Purpose: The effectiveness of statins in improving clinical outcomes among patients with heart failure (HF) undergoing percutaneous coronary intervention (PCI) is unclear. We examined the association between use of statins and clinical outcomes in patients with HF included in the Melbourne Interventional Group registry. Methods: Patients were followed from 30 days to 1 year post-PCI for a primary composite outcome of all-cause mortality and hospitalisation for cardiovascular (CV) causes. Secondary outcomes included major adverse cardiac events (MACE, a composite of all-cause mortality, myocardial infarction and target vessel revascularisation) and hospitalisation for CV causes. Outcomes were compared between statin-treated and non-statin-treated patients (at 30 days post-PCI) using propensity scores to balance for risk factors. Results: Among 991 patients included in the inverse probability-weighted Cox model, statin use had no significant effect on the primary composite outcome [adjusted hazard ratio (aHR), 1.03; 95% confidence interval (CI), 0.68 to 1.56; p = 0.89] , nor MACE (aHR, 0.99; 95% CI, 0.54 to 1.84; p = 0.99) or hospitalisation for CV causes (HR, 1.13; 95% CI, 0.74 to 1.72; p = 0.57). Conclusions: Our results suggest that statin therapy may confer no significant benefits in patients with HF undergoing PCI. However, prospective randomised controlled trials are needed to provide more definitive answers.

    Related items

    Showing items related by title, author, creator and subject.

    • Nutritional and pharmacological regulation of cerebral capillary function
      Pallebage-Gamarallage, Menuka Madhavi Somapala (2012)
      Alzheimer’s disease (AD) is the most common cause of dementia pathologically characterised by neurovascular inflammation, extracellular proteinaceous deposits enriched in amyloid-β (Aβ) and formation of neurofibrillar ...
    • Statins: Antimicrobial resistance breakers or makers?
      Ko, H.; Lareu, Ricky R.; Dix, B.; Hughes, J. (2017)
      © 2017 Ko et al. Introduction. The repurposing of non-antibiotic drugs as adjuvant antibiotics may help break antimicrobial resistance (AMR). Statins are commonly prescribed worldwide to lower cholesterol. They also possess ...
    • Improving Guideline Compliance in Australia With a National Percutaneous Coronary Intervention Outcomes Registry
      Eccleston, D.; Horrigan, M.; Rafter, T.; Holt, G.; Worthley, S.; Sage, P.; Whelan, A.; Reid, Christopher; Thompson, P. (2016)
      © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).Background: Secondary prevention strategies after percutaneous coronary ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.